Clinical trial NCT01513291 (phase 2, status: completed)
Conditions: migraine, headache
ICD codes: G43.B1, G43.D1, G43.B0, G43.D0, G43.A1, G43.411, G43.419, G44.81, G44.86, R51.9, G44.53, G44.83, G44.84, G44.85
Drugs: mk-6096, placebo
SMILES: C[C@@H]1CC[C@@H](COC2=CC=C(F)C=N2)CN1C(=O)C1=CC(C)=CC=C1C1=NC=CC=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  History of migraine with or without aura for >1 year and with ≥4 and ≤14 migraine days
             per month in the 3 months prior to study

          -  Male, female not of reproductive potential, or female of reproductive potential who is
             not pregnant by pregnancy test and agrees to use acceptable contraception

        Exclusion Criteria:

          -  Pregnancy, breast-feeding, or expecting to become pregnant

          -  Planning to donate egg or sperm during the study or within 90 days after last dose of
             study medication

          -  Basilar or hemiplegic migraine headache

          -  >50 years old at the age of migraine onset

          -  ≥15 headache-days per month or medication taken for acute migraine or other headaches
             on more than 10 days per month in any of the three months prior to study

          -  Migraine prophylactic medication (defined as medication taken daily to prevent
             migraines) taken in the 30 days prior to study

          -  History of narcolepsy, cataplexy, circadian rhythm disorder, parasomnia, sleep related
             breathing disorder, restless legs syndrome, periodic limb movement disorder, excessive
             daytime sleepiness or difficulty sleeping due to a medical condition (e.g., asthma,
             gastroesophageal reflux disease, etc.)

          -  Clinical, laboratory, or electrocardiogram (ECG) evidence of uncontrolled
             hypertension, uncontrolled diabetes, human immunodeficiency virus (HIV) disease, or
             significant pulmonary, renal, hepatic, endocrine, or other systemic disease

          -  Myocardial infarction, unstable angina, coronary artery bypass surgery, or other
             revascularization procedure, stroke, or transient ischemic attack within 3 months of
             study

          -  Other confounding pain syndromes (i.e., condition requiring daily use of opioids),
             psychiatric conditions such as uncontrolled major depression, dementia or significant
             neurological disorders other than migraine

          -  Imminent risk of self-harm, based on clinical interview and responses on the Columbia
             Suicidality Severity Rating Scale (C-SSRS), or of harm to others. Exclude any
             prospective participant reporting suicidal ideation with intent, with or without a
             plan in the past 2 months or suicidal behavior in the past 6 months

          -  History of malignancy ≤5 years prior to study, except for adequately treated basal
             cell or squamous cell skin cancer or in situ cervical cancer

          -  History of hypersensitivity to more than two chemical classes of drugs, including
             prescription and over-the-counter medications

          -  Recent history (within the past 1 year) or current evidence of drug or alcohol abuse
             or "recreational use" of illicit drugs or prescription medications

          -  Donated blood products or has had phlebotomy of >300 ml within 8 weeks of study, or
             intends to donate blood products or receive blood products within 30 days before study
             and throughout study

          -  Consumption of 3 or more alcoholic drinks per day

          -  Body Mass Index >40 kg/m^2

          -  History of transmeridian travel (across >3 time zones) or shift work (defined as
             permanent night shift or rotating day/night shift work) within the past 2 weeks or
             anticipates needing to travel (across >3 time zones) at any time during the study.